Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Madrigal Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Non-alcoholic Steatohepatitis

Treatments: Drug: MGL-3196; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02912260

MGL-3196-05

Details and patient eligibility

About

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).

Enrollment: 125 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria. Participants who meet all of the following criteria will be eligible to participate in the study:

• Must be willing to participate in the study and provide written informed consent;

• Male and female adults ≥18 years of age;

• Female participants of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) tests who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control (that is, condoms, diaphragm, nonhormonal intrauterine device [IUD], or sexual abstinence [only if this is in line with the participant's current lifestyle]) throughout the study and for at least 1 month after study completion; hormonal contraception (estrogens stable ≥3 months) and hormonal IUDs are permitted if used with a secondary birth control measure (for example, condoms); or female participants of non-child bearing potential (that is, surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]); Male participants who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must be either surgically sterile (confirmed by documented azoospermia >90 days after the procedure) or agree to use a condom with spermicide. All male participants must agree not to donate sperm from the first dose of study drug until 1 month after study completion;

• Must have confirmation of ≥10% liver fat content on magnetic resonance imaging proton density fat fraction;

• Biopsy-proven NASH. Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a non-alcoholic fatty liver disease activity score (NAS) of ≥4 with a score of 1 or more in each of the following NAS components:

  • Steatosis (scored 0 to 3),
  • Ballooning degeneration (scored 0 to 2), and
  • Lobular inflammation (scored 0 to 3);

• Must have documented historical (3 weeks to 6 months prior to the study entry) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels consistent with the screening ALT and AST values.

Exclusion Criteria. Participants who meet any of the following criteria will be excluded from participation in the study:

Note: Unless otherwise specified, repeat testing may be performed in consultation with the Medical Monitor.

• History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening;
• Hyperthyroidism;
• Participants on thyroid replacement therapy (with exceptions);
• Prior or planned (during the study period) bariatric surgery (for example, gastroplasty, roux-en-Y gastric bypass);
• Type 1 diabetes;
• Uncontrolled Type 2 diabetes defined as Hemoglobin A1c (HbA1c) ≥ 9.5% at screening (participants with HbA1c ≥ 9.5% may be rescreened);
• Use of obeticholic acid, ursodeoxycholic acid (Ursodiol® and Urso®), high dose vitamin E (>400 IU/day) unless on stable dose of vitamin E >400 IU/day for at least 6 months at the time of liver biopsy, or pioglitazone within 90 days prior to enrollment or since screening biopsy, whichever is longer;
• Presence of cirrhosis on liver biopsy (stage 4 fibrosis);
• Platelet count < 140,000/mm^3;
• Clinical evidence of hepatic decompensation;
• Evidence of other forms of chronic liver disease;
• Active, serious medical disease with likely life expectancy <2 years;
• Participation in an investigational new drug trial in the 30 days prior to randomization; or
• Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the participant, or interfere with the study outcomes.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

125 participants in 2 patient groups, including a placebo group

MGL-3196

Experimental group

Description:

Study Drug

Treatment:

Drug: MGL-3196

Placebo

Placebo Comparator group

Description:

Matching Placebo

Treatment:

Drug: Placebo